Novotech Releases Report on Global Bladder Cancer Clinical Trials, Offering Insights for Oncology Advancement
Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, has released an in-depth report, Bladder Cancer – Global Clinical Trial Landscape 2024, offering key insights for stakeholders across the oncology and clinical research sectors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241120379204/en/
Bladder cancer remains a significant health challenge worldwide, with over 614,000 new cases and 220,600 deaths recorded in 2022. Novotech’s latest report provides a detailed examination of the evolving landscape in bladder cancer research, with a focus on clinical trial trends, emerging therapeutic strategies, and regional variations in patient outcomes.
Key Highlights from the Report:
- Bladder Cancer Statistics: A thorough analysis of incidence and survival data, highlighting that Europe and Asia account for the majority of global cases.
- Clinical Trial Landscape: An overview of over 1,500 bladder cancer clinical trials initiated since 2019, with North America, Asia-Pacific, and Europe leading in trial volume.
- Advancements in Treatment: Exploration of innovative therapies, including immunotherapy, targeted treatments, and combination therapies, which are opening new avenues in bladder cancer care.
- Future Projections: Bladder cancer cases are projected to exceed 1.2 million annually by 2050, underscoring the urgent need for advanced treatment options and accessible healthcare solutions.
This report explores valuable information for biotech professionals, oncologists, researchers and scientists. By examining trial density, recruitment efficiencies, and regional disparities in treatment outcomes, the report provides actionable insights for those aiming to enhance the efficiency and effectiveness of bladder cancer trials.
To access the full report and gain a deeper understanding of the trends shaping bladder cancer research, download the report here.
About NovotechNovotech-CRO.com
Founded in 1997, Novotech is a global full-service clinical Contract Research Organization (CRO) focused on partnering with biotech companies to accelerate the development of advanced and novel therapeutics at every phase.
Recognized for its industry-leading contributions, Novotech has received numerous prestigious awards, including the Frost & Sullivan 2024 Global Biotech CRO of the year award, Clinical Trials Arena Excellence Awards 2024, 2024 Employer of Choice, 2024 Great Place to Work in the US, 2024 Brandon Hall Gold Award, CRO Leadership Award 2023, the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2023, the Asia-Pacific Contract Research Organization Company of the Year Award since 2006.
The Company offers a comprehensive suite of services including laboratories, Phase I facilities, drug development consulting, regulatory expertise, and has experience with over 5,000 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. With a presence in 34 office locations and a dedicated team of 3,000+ professionals worldwide, Novotech is a trusted end-to-end strategic partner of choice.
For more information or to speak to an expert team member visit www.Novotech-CRO.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20241120379204/en/
Contacts
Media
Toyna Chin
mediacontact@novotech-cro.com
USA: +1 415 364 8135
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Diagnostics.ai Launches Industry's First CE-IVDR Certified Transparent AI Platform for Molecular Diagnostics as Regulatory Deadlines take Effect29.5.2025 09:13:00 EEST | Press release
Revolutionary Platform Sets New Benchmark for Transparency and Compliance in Diagnostic AI As the May 26th CE-IVDR compliance deadline comes into effect, Diagnostics.ai launches the industry’s first fully-transparent machine learning platform for clinical real-time PCR diagnostics – demonstrating exactly how each result was achieved, a first for molecular-testing machine learning. The technology is backed by over 15 years of experience and millions of successfully processed samples with >99.9% proven accuracy. The CE-IVDR Strategic Advantage Platform is Diagnostics.ai's response to the new wave of stringent EU regulations under the In Vitro Diagnostic Medical Devices Regulation (IVDR), which demand heightened standards for diagnostic accuracy, reproducibility, and algorithm transparency. “While most diagnostic algorithms remain an impenetrable ‘black box,’ the PCR.AI API was engineered with transparency included from the ground up,” said Aron Cohen, Chief Executive Officer of Diagnosti
From Ancient Grounds to an Intelligent Future: The 1st International Humanoid Olympiad Launches in Olympia, Greece29.5.2025 01:47:00 EEST | Press release
This year, Olympia, Greece, the birthplace of the Olympic Games, welcomes the inaugural International Humanoid Olympiad. From August 29th to September 2nd, at the International Olympic Academy in Olympia, humanoid robots will participate in demonstrations and Olympic-inspired games, showcasing their dexterity and intelligence, while global leaders in robotics and AI will share insights through expert talks and workshops. Blending millennia-old values, ethos, and ideals with a bold vision for the future, the event will spotlight how human creativity and robotics are shaping the future. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250528788233/en/ This global gathering brings together state-of-the-art humanoid robots in spectacular showcases designed to captivate audiences of all ages and backgrounds while their creators, researchers, engineers, students, and visionaries are pushing the boundaries of what intelligent machine
Mary Kay Inc. Awards 10 Grants to Young Innovators at 2025 Regeneron International Science and Engineering Fair28.5.2025 23:29:00 EEST | Press release
Mary Kay Inc., a global advocate for furthering young women’s education and encouraging youth to follow their STEM dreams, returned for a second year as a Special Awards Organization at the Regeneron International Science and Engineering Fair (Regeneron ISEF) in Columbus, Ohio. Ten grants totaling nearly $10,000 were awarded to standout high school-aged students excelling in innovative projects spanning topics from finding cures for cancers affecting women to sustainable packaging innovation and protecting our planet’s most valuable resources. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250528325390/en/ Kristin Dasaro, Director, Package Engineering and Sustainability at Mary Kay, greets Brazilian cancer researcher, Carolina de Araujo Pereira da Silva, who received back-to-back awards from Mary Kay for innovative findings in the malignancy of tumors. (Photo Credit: Mary Kay Inc.) Each year, the event convenes nearly 2,000
Duravant Completes Acquisition of Pattyn28.5.2025 20:44:00 EEST | Press release
Duravant LLC (“Duravant”), a global engineered equipment and automation solutions provider to the protein processing, food sorting and handling, packaging, and material handling sectors, announced the completion of its acquisition of the Pattyn Group BV (“Pattyn”), a leading manufacturer of packaging automation systems headquartered in Bruges, Belgium. The transaction was first announced on February 7, 2025, and was completed today. With over 70 years of expertise, Pattyn is a trusted partner for companies looking to automate bulk packaging operations in industries ranging from food and ingredients to non-food applications. Pattyn has been a world-renowned brand specializing in bag-in-box packaging technology, and their comprehensive end-of-line solutions span the entire packaging process from case erecting and bag inserting to weigh filling, bag and case closing, and palletizing. “We are extremely excited to welcome Pattyn to the Duravant family,” said Mike Kachmer, Chairman and CEO o
Rimini Street Appoints Vijay Kumar as EVP and Chief Operating Officer28.5.2025 19:00:00 EEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, management and innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced the appointment of Vijay Kumar as executive vice president (EVP) and chief operating officer (COO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250528704180/en/ Rimini Street Appoints Vijay Kumar as EVP and Chief Operating Officer In this role, Mr. Kumar leads product management, service strategy and offerings for Rimini Street’s “Support, Optimize and Innovate” solutions and oversees Rimini Street’s Global Capability Centers (GCC). Mr. Kumar also drives operational efficiency and innovation of the portfolio to increase profitability and accelerate top line revenue growth. New COO Brings Broad Operational Experience and Capabilities Kumar is a seasoned technology executive with more than 25 yea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom